Driven by science, focused on people.

ABCL635 is a potential first-in-class antibody medicine for the non-hormonal treatment of VMS (commonly known as hot flashes) associated with menopause. ABCL635 specifically targets NK3R, a clinically validated complex membrane protein found on KNDy neurons in the infundibular nucleus of the hypothalamus that helps regulate body temperature. ABCL635 is the first AbCellera-led program generated using our GPCR and ion channel technologies, and we anticipate initiation of clinical trials in Q3 of 2025.

ABCL575 is an investigative monoclonal antibody for the treatment of moderate-to-severe atopic dermatitis (AD), with potential applications to other inflammatory and autoimmune conditions. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. It has been engineered with a modified Fc domain to support Fc-silencing and half-life extension. In preclinical studies, ABCL575 shows potent inhibition of T cell-mediated inflammatory pathways, favorable tolerability, and an in vivo half-life that is expected to support less frequent dosing than current clinical-stage molecules. ABCL575 is projected to enter Phase 1 clinical trials in Q3 of 2025.